REG - Cambridge Cognition - Notice of Results

Cambridge Cognition HoldingsAnnouncement

31/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220331:nRSe6763Ga&default-theme=true

RNS Number : 6763G  Cambridge Cognition Holdings PLC  31 March 2022

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Notice of Preliminary Results Release

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, will announce its preliminary
results for the year ended 31 December 2021 on 12 April 2022.

 

 

For further information, contact:

 Cambridge Cognition Holdings Plc             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Steven Powell, Chairman
 Panmure Gordon (NOMAD and Joint Broker)      Tel: 020 7886 2500

 Freddy Crossley / Emma Earl / Mark Rogers    (Corporate Advisory)

 Rupert Dearden                               (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)       Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBIGDXCSXDGDG